Celadon Pharmaceuticals (LSE:CEL) Accounts Payable & Accrued Expense : €0.48 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Accounts Payable & Accrued Expense?

Celadon Pharmaceuticals's quarterly accounts payable & accrued expense increased from Dec. 2022 (€0.72 Mil) to Jun. 2023 (€1.52 Mil) but then declined from Jun. 2023 (€1.52 Mil) to Dec. 2023 (€0.48 Mil).

Celadon Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.72 Mil) but then declined from Dec. 2022 (€0.72 Mil) to Dec. 2023 (€0.48 Mil).

Celadon Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Celadon Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Accounts Payable & Accrued Expense Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

0.80

0.72

0.48

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			0.05	1.38	0.72	1.52	0.48

Celadon Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines